{"id":"tp-47043","type":"article-newspaper","title":"Edwards Says PASCAL Outperformed Medical Therapy on Tricuspid Trial Endpoint","author":"John Kim","publisher":"TOKENPOST Inc.","url":"https://www.tokenpost.com/news/business/47043","datePublished":"2026-11-02T23:35:20.000Z","dateModified":"2026-11-02T23:35:20.000Z","language":"en","abstract":"At one year, 80% of PASCAL-treated patients had moderate or lower tricuspid regurgitation, compared with 30% of control patients.","section":"Business","references":[]}